This finding suggests that targeting the POSTN-NOTCH axis might be a promising therapeutic strategy to curb SCLC progression and liver metastasis, offering potential insights into the development of novel treatment modalities for this aggressive disease (Fig. 8). The gene discussed is POSTN; the disease is small cell lung carcinoma.